復星醫藥(02196.HK)出售和睦家醫院和診所權益料錄收益16.5億人幣
復星醫藥(02196.HK)(600196.SH)公布,擬向美國上市公司新風天域(NFC)出售運營「和睦家」醫院及診所的合夥企業權益,總值約5.23億美元。同時,公司以總額9,400萬美元的對價認購NFC擬發行940萬股,約佔NFC經擴大後全部已發行股份6.62%。
公司預計將因上述交易錄得收益約16.47億元人民幣(企業所得稅前,未經審核),所得款項將用於歸還帶息債務及補充營運資金,交易將有利於優化集團財務結構。
「和睦家」為中國領先的高端外資醫療連鎖服務機構,為中外高端人群提供預防保 健、疾病診斷、治療至康復的一站式、連續性醫療服務。「和睦家」自1997年成立以來,於國內一線城市中心地帶佈局,並已在全國一線、二線城市共設 有並運營7家中大型高端醫院及14家高端診所。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.